Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment

Dantzer, 2008, From inflammation to sickness and depression: when the immune system subjugates the brain, Nat Rev Neurosci, 9, 46, 10.1038/nrn2297

Khandaker, 2014, Association of serum interleukin-6 and c-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitdunal study, JAMA Psychiatry, 71, 1121, 10.1001/jamapsychiatry.2014.1332

McFarland, 2007, Multiple sclerosis: a complicated picture of autoimmunity, Nat Immunol, 8, 913, 10.1038/ni1507

Dantzer, 2004, Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity, Eur J Pharmacol, 500, 399, 10.1016/j.ejphar.2004.07.040

Miller, 2009, Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression, Biol Psychiatry, 65, 732, 10.1016/j.biopsych.2008.11.029

Zandi, 2011, Disease-relevant autoantibodies in first episode schizophrenia, J Neurol, 258, 686, 10.1007/s00415-010-5788-9

2002

2001

Carson, 2006, CNS immune privilege: hiding in plain sight, Immunol Rev, 213, 48, 10.1111/j.1600-065X.2006.00441.x

Hanisch, 2007, Microglia: active sensor and versatile effector cells in the normal and pathologic brain, Nat Neurosci, 10, 1387, 10.1038/nn1997

Kirkbride, 2012, Incidence of schizophrenia and other psychoses in England, 1950–2009: a systematic review and meta-analyses, PloS One, 7, e31660, 10.1371/journal.pone.0031660

Khandaker, 2014, Life course approach to specific mental disorders: schizophrenia and related psychosis, 61

Brown, 2010, Prenatal infection and schizophrenia: a review of epidemiologic and translational studies, Am J Psychiatry, 167, 261, 10.1176/appi.ajp.2009.09030361

Khandaker, 2012, Childhood infection and adult schizophrenia: a meta-analysis of population-based studies, Schizophr Res, 139, 161, 10.1016/j.schres.2012.05.023

Khandaker, 2013, Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies, Psychol Med, 43, 239, 10.1017/S0033291712000736

Miller, 2011, Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects, Biol Psychiatry, 70, 663, 10.1016/j.biopsych.2011.04.013

Canetta, 2014, Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort, Am J Psychiatry, 171, 960, 10.1176/appi.ajp.2014.13121579

Gardner, 2013, Neonatal levels of acute phase proteins and later risk of non-affective psychosis, Transl Psychiatry, 3, e228, 10.1038/tp.2013.5

Khandaker, 2014, Childhood Epstein-Barr Virus infection and subsequent risk of psychotic experiences in adolescence: A population-based prospective serological study, Schizophr Res, 158, 19, 10.1016/j.schres.2014.05.019

Torrey, 2012, Toxoplasma gondii and other risk factors for schizophrenia: an update, Schizophr Bull (Bp), 38, 642, 10.1093/schbul/sbs043

Khandaker, 2014, A population-based study of atopic disorders and inflammatory markers in childhood before psychotic experiences in adolescence, Schizophr Res, 152, 139, 10.1016/j.schres.2013.09.021

Benros, 2011, Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study, Am J Psychiatry, 168, 1303, 10.1176/appi.ajp.2011.11030516

Eaton, 2006, Association of schizophrenia and autoimmune diseases: linkage of Danish national registers, Am J Psychiatry, 163, 521, 10.1176/appi.ajp.163.3.521

Engelhardt, 2009, The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction, Semin Immunopathol, 31, 497, 10.1007/s00281-009-0177-0

Shi, 2009, Common variants on chromosome 6p22.1 are associated with schizophrenia, Nature, 460, 753, 10.1038/nature08192

Stefansson, 2009, Common variants conferring risk of schizophrenia, Nature, 460, 744, 10.1038/nature08186

2014, Biological insights from 108 schizophrenia-associated genetic loci, Nature, 511, 421, 10.1038/nature13595

Andreassen, 2014, Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci, Mol Psychiatry

Potvin, 2008, Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review, Biol Psychiatry, 63, 801, 10.1016/j.biopsych.2007.09.024

Upthegrove, 2014, Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis, Schizophr Res, 155, 101, 10.1016/j.schres.2014.03.005

Wium-Andersen, 2014, Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study, Schizophr Bull (Bp), 40, 1117, 10.1093/schbul/sbt120

Ganguli, 1993, Autoimmunity in schizophrenia: a review of recent findings, Ann Med, 25, 489, 10.3109/07853899309147317

Garver, 2003, Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype, Neuropsychopharmacology, 28, 1515, 10.1038/sj.npp.1300217

Hayes, 2014, Inflammatory molecular signature associated with infectious agents in psychosis, Schizophr Bull (Bp), 40, 963, 10.1093/schbul/sbu052

Stojanovic, 2014, Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms, Psychoneuroendocrinology, 41, 23, 10.1016/j.psyneuen.2013.12.005

de Witte, 2014, Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment, Schizophr Res, 154, 23, 10.1016/j.schres.2014.02.005

Maes, 1994, Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine, Acta Psychiatr Scand, 89, 346, 10.1111/j.1600-0447.1994.tb01527.x

Maes, 1995, Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers, J Psychiatr Res, 29, 141, 10.1016/0022-3956(94)00049-W

Maes, 1997, In vivo immunomodulatory effects of clozapine in schizophrenia, Schizophr Res, 26, 221, 10.1016/S0920-9964(97)00057-1

Yirmiya, 2011, Immune modulation of learning, memory, neural plasticity and neurogenesis, Brain Behav Immun, 25, 181, 10.1016/j.bbi.2010.10.015

Harrison, 2014, Peripheral Inflammation Acutely Impairs Human Spatial Memory via Actions on Medial Temporal Lobe Glucose Metabolism, Biol Psychiatry, 76, 585, 10.1016/j.biopsych.2014.01.005

Eraly, 2014, Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk, JAMA Psychiatry, 71, 423, 10.1001/jamapsychiatry.2013.4374

Danese, 2008, Elevated inflammation levels in depressed adults with a history of childhood maltreatment, Arch Gen Psychiatry, 65, 409, 10.1001/archpsyc.65.4.409

Walker, 2013, NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice, Neuropsychopharmacology, 38, 1609, 10.1038/npp.2013.71

Reichenberg, 2001, Cytokine-associated emotional and cognitive disturbances in humans, Arch Gen Psychiatry, 58, 445, 10.1001/archpsyc.58.5.445

Santambrogio, 2001, Developmental plasticity of CNS microglia, Proc Natl Acad Sci USA, 98, 6295, 10.1073/pnas.111152498

Ransohoff, 2009, Microglial physiology: unique stimuli, specialized responses, Annu Rev Immunol, 27, 119, 10.1146/annurev.immunol.021908.132528

Perry, 2010, Microglia in neurodegenerative disease, Nat Rev Neurol, 6, 193, 10.1038/nrneurol.2010.17

van Berckel, 2008, Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study, Biol Psychiatry, 64, 820, 10.1016/j.biopsych.2008.04.025

Doorduin, 2009, Neuroinflammation in schizophrenia-related psychosis: a PET study, J Nucl Med, 50, 1801, 10.2967/jnumed.109.066647

Schroder, 2006, Signal integration between IFNgamma and TLR signalling pathways in macrophages, Immunobiology, 211, 511, 10.1016/j.imbio.2006.05.007

Brennand, 2011, Modelling schizophrenia using human induced pluripotent stem cells, Nature, 473, 221, 10.1038/nature09915

Lehmann-Facius, 1937, Über die Liquordiagnose der Schizophrenien, Klinische Wochenschrift, 16, 1646, 10.1007/BF01776787

Lachance, 2014, Biomarkers of gluten sensitivity in patients with non-affective psychosis: a meta-analysis, Schizophr Res, 152, 521, 10.1016/j.schres.2013.12.001

Rothermundt, 2001, Review of immunological and immunopathological findings in schizophrenia, Brain Behav Immun, 15, 319, 10.1006/brbi.2001.0648

Deakin, 2014, Antibodies to the N-methyl-D-aspartate receptor and other synaptic proteins in psychosis, Biol Psychiatry, 75, 284, 10.1016/j.biopsych.2013.07.018

Lennox, 2012, Antibody-mediated encephalitis: a treatable cause of schizophrenia?, Br J Psychiatry, 200, 92, 10.1192/bjp.bp.111.095042

Parthasarathi, 2006, Psychiatric presentation of voltage-gated potassium channel antibody-associated encephalopathy. Case report, Br J Psychiatry, 189, 182, 10.1192/bjp.bp.105.012864

Steiner, 2013, Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis, JAMA Psychiatry, 70, 271, 10.1001/2013.jamapsychiatry.86

Dalmau, 2011, Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis, Lancet Neurol, 10, 63, 10.1016/S1474-4422(10)70253-2

Titulaer, 2013, Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study, Lancet Neurol, 12, 157, 10.1016/S1474-4422(12)70310-1

Pearlman, 2014, Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder, Schizophr Res, 157, 249, 10.1016/j.schres.2014.05.001

Pomarol-Clotet, 2006, Psychological effects of ketamine in healthy volunteers. Phenomenological study, Br J Psychiatry, 189, 173, 10.1192/bjp.bp.105.015263

Fromer, 2014, De novo mutations in schizophrenia implicate synaptic networks, Nature, 506, 179, 10.1038/nature12929

Nikkila, 2001, Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia, Schizophr Res, 49, 99, 10.1016/S0920-9964(99)00218-2

Nikkila, 1995, Abnormal distributions of T-lymphocyte subsets in the cerebrospinal fluid of patients with acute schizophrenia, Schizophr Res, 14, 215, 10.1016/0920-9964(94)00039-B

Busse, 2012, Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations?, Brain Behav Immun, 26, 1273, 10.1016/j.bbi.2012.08.005

Miller, 2013, Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects, Biol Psychiatry, 73, 993, 10.1016/j.biopsych.2012.09.007

Meyer, 2009, Neural basis of psychosis-related behaviour in the infection model of schizophrenia, Behav Brain Res, 204, 322, 10.1016/j.bbr.2008.12.022

Carlsson, 1990, Schizophrenia: a subcortical neurotransmitter imbalance syndrome?, Schizophr Bull (Bp), 16, 425, 10.1093/schbul/16.3.425

Schwarcz, 2002, Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities, J Pharmacol Exp Ther, 303, 1, 10.1124/jpet.102.034439

Stone, 1993, Neuropharmacology of quinolinic and kynurenic acids, Pharmacol Rev, 45, 309

Schwieler, 2005, Prostaglandin-mediated control of rat brain kynurenic acid synthesis—opposite actions by COX-1 and COX-2 isoforms, J Neural Transm, 112, 863, 10.1007/s00702-004-0231-y

Akhondzadeh, 2007, Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial, Schizophr Res, 90, 179, 10.1016/j.schres.2006.11.016

Muller, 2010, Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment, Schizophr Res, 121, 118, 10.1016/j.schres.2010.04.015

Sarkar, 2010, The immunoregulatory role of dopamine: an update, Brain Behav Immun, 24, 525, 10.1016/j.bbi.2009.10.015

Besser, 2005, Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both, J Neuroimmunol, 169, 161, 10.1016/j.jneuroim.2005.07.013

Levite, 2001, Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function, Eur J Immunol, 31, 3504, 10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F

Ilani, 2001, A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes, Proc Natl Acad Sci USA, 98, 625, 10.1073/pnas.98.2.625

Nagai, 1996, Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease, Neurology, 46, 791, 10.1212/WNL.46.3.791

Woods, 1998, Is schizophrenia a Progressive Neurodevelopmental Disorder? Toward a Unitary Pathogenetic Mechanism, Am J Psychiatry, 155, 1661, 10.1176/ajp.155.12.1661

Harrison, 1999, The neuropathology of schizophrenia. A critical review of the data and their interpretation, Brain, 122, 593, 10.1093/brain/122.4.593

Veijola, 2014, Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication, PloS One, 9, e101689, 10.1371/journal.pone.0101689

Flatow, 2013, Meta-analysis of oxidative stress in schizophrenia, Biol Psychiatry, 74, 400, 10.1016/j.biopsych.2013.03.018

Davis, 2012, Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study, Brain, 135, 2809, 10.1093/brain/aws190

Iwashyna, 2010, Long-term cognitive impairment and functional disability among survivors of severe sepsis, JAMA, 304, 1787, 10.1001/jama.2010.1553

Khandaker, 2011, Cognitive and functional impairment after severe sepsis, JAMA, 305, 673, 10.1001/jama.2011.142

Murray, 1987, Is schizophrenia a neurodevelopmental disorder?, BMJ (Clin Res Ed), 295, 681, 10.1136/bmj.295.6600.681

Weinberger, 1987, Implications of normal brain development for the pathogenesis of schizophrenia, Arch Gen Psychiatry, 44, 660, 10.1001/archpsyc.1987.01800190080012

Meyer, 2010, Epidemiology-driven neurodevelopmental animal models of schizophrenia, Prog Neurobiol, 90, 285, 10.1016/j.pneurobio.2009.10.018

Smith, 2007, Maternal immune activation alters fetal brain development through interleukin-6, J Neurosci, 27, 10695, 10.1523/JNEUROSCI.2178-07.2007

Clarke, 2009, Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia, Am J Psychiatry, 166, 1025, 10.1176/appi.ajp.2009.08010031

Nielsen, 2013, Association Between Parental Hospital-Treated Infection and the Risk of Schizophrenia in Adolescence and Early Adulthood, Schizophr Bull (Bp), 39, 230, 10.1093/schbul/sbr149

Collins, 2012, The interplay between the intestinal microbiota and the brain, Nat Rev Microbiol, 10, 735, 10.1038/nrmicro2876

Cryan, 2012, Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour, Nat Rev Neurosci, 13, 701, 10.1038/nrn3346

Hsiao, 2013, Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders, Cell, 155, 1451, 10.1016/j.cell.2013.11.024

Bravo, 2011, Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve, Proc Natl Acad Sci USA, 108, 16050, 10.1073/pnas.1102999108

Severance, 2012, Gastrointestinal inflammation and associated immune activation in schizophrenia, Schizophr Res, 138, 48, 10.1016/j.schres.2012.02.025

Desbonnet, 2010, Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression, Neuroscience, 170, 1179, 10.1016/j.neuroscience.2010.08.005

O'Mahony, 2005, Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 541, 10.1053/j.gastro.2004.11.050

Schwarz, 2014, Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways, Schizophr Bull (Bp), 40, 787, 10.1093/schbul/sbt105

Laan, 2007, Non-steroidal anti-inflammatory drugs and the risk of psychosis, Eur Neuropsychopharmacol, 17, 309, 10.1016/j.euroneuro.2006.09.003

Stolk, 2007, The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study, Pharmacopsychiatry, 40, 111, 10.1055/s-2007-977714

Laan, 2010, Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, 71, 520, 10.4088/JCP.09m05117yel

Baheti, 2013, A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia, Schizophr Res, 147, 201, 10.1016/j.schres.2013.03.017

Muller, 2002, Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia, Am J Psychiatry, 159, 1029, 10.1176/appi.ajp.159.6.1029

Muller, 2004, COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy, Eur Arch Psychiatry Clin Neurosci, 254, 14, 10.1007/s00406-004-0478-1

Muller, 2005, Clinical effects of COX-2 inhibitors on cognition in schizophrenia, Eur Arch Psychiatry Clin Neurosci, 255, 149, 10.1007/s00406-004-0548-4

Rapaport, 2005, Celecoxib augmentation of continuously ill patients with schizophrenia, Biol Psychiatry, 57, 1594, 10.1016/j.biopsych.2005.02.024

Bresee, 2006, The effects of celecoxib augmentation on cytokine levels in schizophrenia, Int J Neuropsychopharmacol, 9, 343, 10.1017/S1461145705005808

Levkovitz, 2010, A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia, J Clin Psychiatry, 71, 138, 10.4088/JCP.08m04666yel

Chaudhry, 2012, Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment, J Psychopharmacol, 26, 1185, 10.1177/0269881112444941

Webb, 2013, Aspirin as an adjunctive treatment for childhood onset schizophrenia, J Child Adolesc Psychopharmacol, 23, 585, 10.1089/cap.2013.0033

Jhamnani, 2013, Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia, J Neuropsychiatry Clin Neurosci, 25, E06, 10.1176/appi.neuropsych.11120376

Miyaoka, 2008, Minocycline as adjunctive therapy for schizophrenia: an open-label study, Clin Neuropharmacol, 31, 287, 10.1097/WNF.0b013e3181593d45

Miyaoka, 2007, Possible antipsychotic effects of minocycline in patients with schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry, 31, 304, 10.1016/j.pnpbp.2006.08.013

Chaves, 2010, Functional neuroimaging of minocycline's effect in a patient with schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry, 34, 550, 10.1016/j.pnpbp.2010.01.020

Kelly, 2011, Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms, Schizophr Res, 133, 257, 10.1016/j.schres.2011.08.005

Sommer, 2012, Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis, J Clin Psychiatry, 73, 414, 10.4088/JCP.10r06823

Mukherjee, 2001, Risk of cardiovascular events associated with selective COX-2 inhibitors, JAMA, 286, 954, 10.1001/jama.286.8.954

Raison, 2013, A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers, JAMA Psychiatry, 70, 31, 10.1001/2013.jamapsychiatry.4

Carvalho, 2013, Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system, J Affect Disord, 148, 136, 10.1016/j.jad.2012.10.036

Zunszain, 2013, Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties, Mol Psychiatry, 18, 1236, 10.1038/mp.2013.87

Zarate, 2006, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression, Arch Gen Psychiatry, 63, 856, 10.1001/archpsyc.63.8.856

Murrough, 2013, Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial, Am J Psychiatry, 170, 1134, 10.1176/appi.ajp.2013.13030392

Zarate, 2013, A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression, Biol Psychiatry, 74, 257, 10.1016/j.biopsych.2012.10.019

Bullmore, 2014, Immunologic therapeutics and psychotic disorders, Biol Psychiatry, 75, 260, 10.1016/j.biopsych.2013.12.006

Danesh, 2008, Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review, PLoS Med, 5, e78, 10.1371/journal.pmed.0050078

Pradhan, 2001, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus, JAMA, 286, 327, 10.1001/jama.286.3.327